Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-
-Company To Continue Work With Torreya Capital On Asset Monetization-
Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.
As previously disclosed, the Company engaged Torreya Capital to facilitate the exploration of a range of strategic options, including potential in-licensing or out-licensing of commercial stage assets. While the Company continues to work with Torreya Capital on identifying and evaluating potential strategic options with the goal of maximizing shareholder value, the Company is currently focused on the sale of its existing assets, including Lefamulin and IV Fosfomycin.
https://finance.yahoo.com/news/nabriva-therapeutics-provides-corporate-120100923.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.